MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
- Intelligence Anchor: MapLight shares sink on mixed ph. 2 schizophrenia readout
- Core Takeaway: MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
- Signal Velocity: 5 score across 7 independent media sources and 7 indexed articles.
- Forecast Model: Story predicted to decelerate within 24h.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Yahoo Finance first reported a $1 billion loss in market capitalization after the company's once-daily dose of ML-007C-MA failed to meet trial expectations. The sharp market reaction followed the release of topline results from the ZEPHYR trial, which Psychiatric Times and Fierce Biotech identified as the primary catalyst for the stock's downward trajectory. Contradicting accounts have emerged regarding the nature of the data.
While some outlets describe the results as a trial miss, BioPharma Dive frames the readout as positive for the schizophrenia drug. BioWorld News notes that the company is currently attempting to differentiate its muscarinic agonist from existing market competitors. Broad market trends are also being considered as a factor, with Finimize noting that biotechnology and artificial intelligence stocks have faced recent volatility following mixed sectoral news.
The current state of the company's valuation and its central nervous system research story remain in sharp focus as analysts assess the impact of the ZEPHYR findings.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 54d ago.
Sources (7)
- MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose Yahoo Finance · 56d ago
- Maplight aims to differentiate muscarinic agonist from competitors BioWorld News · 56d ago
- MapLight dives despite positive data for schizophrenia drug BioPharma Dive · 56d ago
- MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus simplywall.st · 56d ago
- Biotech And AI Stocks Got Hit On Mixed News Finimize · 56d ago
- Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia Psychiatric Times · 56d ago
- MapLight shares sink on mixed ph. 2 schizophrenia readout Fierce Biotech · 56d ago
Quick answers
What is the primary product in question?
The drug candidate is ML-007C-MA, a muscarinic agonist intended for the treatment of schizophrenia.
How did the market react to the clinical data?
MPLT stock fell 73%, resulting in a loss of over $1 billion in market capitalization.
What was the result of the ZEPHYR trial?
The data is described as mixed, with some reports noting a trial miss for the once-daily dose while others characterize the overall results as positive.
Will this trend continue gaining momentum or fade within 24 hours?
Cast your anonymous vote to register reader sentiment on news cycle velocity.
Topics
Related trends
5 Things to Know Before the Stock Market Opens on Monday
A surprise lineup of biotech and tech stocks is set to dominate Monday’s market opening, forcing investors to rethink their early‑day playbook.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
Argenx to Buy Forte Biosciences for $2.2 Billion
A $2.2 billion acquisition agreement marks a significant shift in the immunology market, as Argenx moves to absorb Forte Biosciences.
Precise DNA base editing using AlphaFold3-based contact modelling
Researchers are utilizing AlphaFold3-based contact modelling to redesign gene-editing proteins, aiming to improve safety in CRISPR applications.
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead Pharmaceuticals stock reaches five-year highs following successful Phase 3 trial results, while shares of competitor Ionis decline.
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
Tempus AI moves to acquire cancer-tech firm Personalis in a high-stakes stock deal, triggering an immediate downturn in share prices for both companies.